Financing Will Support Development of CeloNova's PzF Nanocoated Devices


August 7, 2017—CeloNova BioSciences, Inc. announced the completion of a 4-year joint financing arrangement with Congruent Investment Partners and SWK Holdings Corporation. The financing will provide growth capital for CeloNova to continue its new product initiatives and focus on patient enrollment in ongoing clinical trials for its devices based on the company's Polyzene-F (PzF) nanocoating technology.

CeloNova's Cobra PzF combines a cobalt-chromium platform design with the company's PzF nanothin polymer.

In early 2017, CeloNova announced US Food and Drug Administration (FDA) approval of the Cobra PzF nanocoated coronary stent to treat patients with symptomatic ischemic heart disease, including those with diabetes mellitus. The device was subsequently launched in the United States. The Cobra PzF stent received CE Mark approval in 2012 and was launched in Europe and the Middle East in 2013.

CeloNova is continuing to study the Cobra PzF device in the COBRA REDUCE trial, which began enrollment in February 2016. The trial will evaluate whether the stent can help reduce bleeding as compared with drug-eluting stents, by shortening the duration of dual antiplatelet therapy to 14 days in patients who are at high-risk for bleeding and require treatment for coronary artery disease.

Congruent Investment Partners manages investment funds with long-term capital that make lower middle market mezzanine and equity investments of $5 million to $40 million across a broad range of industries. SWK Holdings Corporation is a specialized finance company with a focus on the global health care sector.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.